Posted by Michael Wonder on 25 Mar 2021
Uplinza (inebilizumab-cdon) approved by Japanese Ministry of Health, Labour and Welfare for the prevention of relapses of neuromyelitis optica spectrum disorder
24 March 2021 - Horizon Therapeutics today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation has received manufacturing and marketing approval of Uplinza for the prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica) from the Japanese Ministry of Health, Labour and Welfare.
Mitsubishi Tanabe Pharma Corporation has rights to the development and commercialisation of Uplinza for neuromyelitis optica spectrum disorder as well as other potential future indications in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, Philippines, Singapore and Taiwan.
